Heidi L. Fraser

Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2

Allan Wissner, Heidi L. Fraser, Charles L. Ingalls et al. · Bioorganic & Medicinal Chemistry · 2007 · 75 citations · Full text

Independent Reactive Centers, Drug Targeting, Medicine +8

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as Covalent-Binding, Irreversible Inhibitors of the Kinase Domain of Vascular Endothelial Growth Factor Receptor-2

Allan Wissner, M. Brawner Floyd, Bernard D. Johnson et al. · Journal of Medicinal Chemistry · 2005 · 57 citations · Full text

Bioorganic Chemistry, Boltzmann Distribution, Pharmacotherapy +17

A novel radical cyclization of 2-bromoindoles. Synthesis of hexahydropyrrolo[3,4-b]indoles

Gordon W. Gribble, Heidi L. Fraser, Jeanese C. Badenock · Chemical Communications · 2001 · 40 citations

Novel Radical Cyclization, 1,5-Radical Translocation Process, Engineering +10

Benzo[c][2,7]naphthyridines as inhibitors of PDK-1

Kyung‐Hee Kim, Allan Wissner, Middleton B. Floyd et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 27 citations · Full text

Medicinal Chemistry, Medicine, Organic Chemistry +4

The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1)

Thomas Nittoli, Russell G. Dushin, Charles L. Ingalls et al. · European Journal of Medicinal Chemistry · 2009 · 25 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +11